These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10160470)

  • 41. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
    Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE
    JAMA; 2007 Apr; 297(13):1443-54. PubMed ID: 17405970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of sumatriptan and naproxen for migraine.
    Hill KP; Hope O
    JAMA; 2007 Sep; 298(11):1276; author reply 1276-7. PubMed ID: 17878418
    [No Abstract]   [Full Text] [Related]  

  • 44. [Improper equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
    Ferrari MD; Haan J; Bax WA; van Coevorden RS; Timmerman H; Meijler WJ
    Ned Tijdschr Geneeskd; 1993 Apr; 137(17):846-50. PubMed ID: 8387648
    [No Abstract]   [Full Text] [Related]  

  • 45. [Unjustified equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
    Van Mil JW
    Ned Tijdschr Geneeskd; 1993 Jun; 137(24):1213-4. PubMed ID: 8391659
    [No Abstract]   [Full Text] [Related]  

  • 46. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacologic treatment of acute migraine attack in children].
    Cuvellier JC; Joriot S; Auvin S; Vallée L
    Arch Pediatr; 2005 Mar; 12(3):316-25. PubMed ID: 15734131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sumatriptan, serotonin, migraine, and money.
    Lancet; 1992 Jan; 339(8786):151-2. PubMed ID: 1346014
    [No Abstract]   [Full Text] [Related]  

  • 49. Acute Migraine Treatment.
    Becker WJ
    Continuum (Minneap Minn); 2015 Aug; 21(4 Headache):953-72. PubMed ID: 26252584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein.
    Labruijere S; Chan KY; de Vries R; van den Bogaerdt AJ; Dirven CM; Danser AJ; Kori SH; MaassenVanDenBrink A
    Cephalalgia; 2015 Feb; 35(2):182-9. PubMed ID: 25078720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
    Morren JA; Galvez-Jimenez N
    Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
    Cohen JA; Beall D; Beck A; Rawlings J; Miller DW; Clements B; Pait DG; Batenhorst A
    Clin Ther; 1999 Jan; 21(1):190-204. PubMed ID: 10090435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack].
    Prusiński A; Król F
    Pol Merkur Lekarski; 1998 Mar; 4(21):158-61. PubMed ID: 9640070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nasal sumatriptan: new dosage. For adolescents with migraine: too little benefit.
    Prescrire Int; 2005 Apr; 14(76):45-7. PubMed ID: 15875337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
    Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
    Göbel H; Heinze A; Stolze H; Heinze-Kuhn K; Lindner V
    Cephalalgia; 1999 Sep; 19(7):676-83; discussion 626. PubMed ID: 10524662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.
    Lofland JH; Nash DB
    Pharmacoeconomics; 2005; 23(3):259-74. PubMed ID: 15836007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.